Bibliographic Details
| Title: |
Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination. |
| Authors: |
Ali, Nicole M1,2 (AUTHOR), Herati, Ramin S2 (AUTHOR), Mehta, Sapna A1,2 (AUTHOR) Sapna.Mehta@nyulangone.org, Leonard, Jeanette1 (AUTHOR), Miles, Jake3 (AUTHOR), Lonze, Bonnie E1,4 (AUTHOR), DiMaggio, Charles4 (AUTHOR), Tatapudi, Vasishta S1,2 (AUTHOR), Stewart, Zoe A1,4 (AUTHOR), Alnazari, Nasser1 (AUTHOR), Neumann, Henry J1,2 (AUTHOR), Thomas, Jeffrey1 (AUTHOR), Cartiera, Katarzyna1 (AUTHOR), Weldon, Elaina1 (AUTHOR), Michael, Jennifer1 (AUTHOR), Hickson, Christopher1 (AUTHOR), Whiteson, Harris1 (AUTHOR), Khalil, Karen1 (AUTHOR), Stern, Jeffrey M1,4 (AUTHOR), Allen, Joseph R2 (AUTHOR) |
| Source: |
Transplant Infectious Disease. Dec2023, Vol. 25 Issue 6, p1-6. 6p. |
| Subject Terms: |
*SARS-CoV-2, *KIDNEY transplantation, *VACCINE immunogenicity, *IMMUNE response, *VACCINE effectiveness |
| Abstract: |
Background: Understanding immunogenicity and alloimmune risk following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in kidney transplant recipients is imperative to understanding the correlates of protection and to inform clinical guidelines. Methods: We studied 50 kidney transplant recipients following SARS‐CoV‐2 vaccination and quantified their anti‐spike protein antibody, donor‐derived cell‐free DNA (dd‐cfDNA), gene expression profiling (GEP), and alloantibody formation. Results: Participants were stratified using nucleocapsid testing as either SARS‐CoV‐2‐naïve or experienced prior to vaccination. One of 34 (3%) SARS‐CoV‐2 naïve participants developed anti‐spike protein antibodies. In contrast, the odds ratio for the association of a prior history of SARS‐CoV‐2 infection with vaccine response was 18.3 (95% confidence interval 3.2, 105.0, p < 0.01). Pre‐ and post‐vaccination levels did not change for median dd‐cfDNA (0.23% vs. 0.21% respectively, p = 0.13), GEP scores (9.85 vs. 10.4 respectively, p = 0.45), calculated panel reactive antibody, de‐novo donor specific antibody status, or estimated glomerular filtration rate. Conclusions: SARS‐CoV‐2 vaccines do not appear to trigger alloimmunity in kidney transplant recipients. The degree of vaccine immunogenicity was associated most strongly with a prior history of SARS‐CoV‐2 infection. [ABSTRACT FROM AUTHOR] |
|
Copyright of Transplant Infectious Disease is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
